Aptose Announces Proposed Public Offering of Common Shares
15 juil. 2020 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public...
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
29 juin 2020 07h01 HE
|
Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
12 juin 2020 07h00 HE
|
Aptose Biosciences, Inc.
Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies Plasma from CG-806 treated patients completely inhibited...
Aptose Biosciences Announces Results of Annual Meeting of Shareholders
02 juin 2020 17h49 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association
14 mai 2020 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference
07 mai 2020 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Establishes New At-The-Market Facility
05 mai 2020 16h17 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents...
Aptose Reports Results for the First Quarter 2020
05 mai 2020 16h00 HE
|
Aptose Biosciences, Inc.
CG-806 Phase 1 a/b Study in B Cell Malignancies Now Dosing in Fourth Cohort CG-806 Proposed Starting Dose for Upcoming Phase 1 Study in AML Identified Conference Call and Webcast at 5pm EDT Today ...
Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020
27 avr. 2020 09h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Files Proxy Statement, Announces Online Only Annual General Meeting
24 avr. 2020 07h30 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 24, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...